Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.960-1.060 for the period, compared to the consensus earnings per share estimate of 0.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock traded down $0.60 during trading hours on Thursday, reaching $18.50. The stock had a trading volume of 2,496,893 shares, compared to its average volume of 2,181,445. The company has a market cap of $5.90 billion, a price-to-earnings ratio of 48.69 and a beta of 1.26. Amneal Pharmaceuticals has a 52 week low of $7.66 and a 52 week high of $19.26. The business’s 50 day moving average price is $15.99 and its 200-day moving average price is $14.19.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.03. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AMRX shares. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. UBS Group lifted their price objective on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.60.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 17.30% of the company’s stock.

Key Headlines Impacting Amneal Pharmaceuticals

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results beat expectations: Amneal reported $796 million in revenue, $58 million in GAAP net income, and adjusted diluted EPS of $0.30, above the roughly $0.24 consensus estimate. Adjusted EBITDA reached $206 million, while EPS increased from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised or reaffirmed at a favorable level: Amneal expects 2026 revenue of $3.1 billion to $3.2 billion and EPS of $0.96 to $1.06. The EPS range’s midpoint is above the approximately $0.97 analyst consensus, supporting the bullish reaction. Amneal earnings and guidance
• Positive Sentiment: Lower financing costs could support future earnings: A successful July debt repricing is expected to reduce interest expense, potentially improving cash flow and profitability. Debt repricing and Q2 results
• Neutral Sentiment: The earnings-call transcript focused on the quarter’s performance and updated outlook. Investors will likely look for additional details on product launches, demand trends, and the company’s debt reduction plans. Q2 2026 earnings call transcript
• Negative Sentiment: Valuation and profitability risks remain: AMRX trades at an elevated earnings multiple, while its reported net margin remains modest and return on equity is deeply negative. These factors could encourage profit-taking after the earnings-driven advance.

Institutional Trading of Amneal Pharmaceuticals

Several hedge funds have recently made changes to their positions in AMRX. Kemnay Advisory Services Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Federated Hermes Inc. boosted its position in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank increased its holdings in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the last quarter. Transamerica Financial Advisors LLC raised its position in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the period. Finally, Focus Partners Wealth purchased a new stake in Amneal Pharmaceuticals in the third quarter valued at approximately $42,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.